Richard S Hudes MD FACR

Radiation Oncology•Baltimore, MD

www.ROHBaltimore.com

Join to View Full Profile

900 Caton AvenueBaltimore, MD 21229
Phone+1 667-234-2965
Fax+1 410-951-4002

Summary

Dr. Richard Hudes is a radiation oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Greater Baltimore Medical Center and he is Chief of Radiation Oncology at Ascension Saint Agnes Hospital. He received his medical degree from Medical College of Georgia and has been in practice 24 years. He is experienced in stereotactic radiosurgery and prostate seed therapy. He has more than 20 publications and over 500 citings. He has been named "Top Doc" more than a dozen times in Baltimore Magazine.

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Radiation Oncology, 1996 - 2000
NYU Grossman Long Island School of MedicineInternship, Internal Medicine, 1995 - 1996
Medical College of Georgia at Augusta UniversityClass of 1995

Certifications & Licensure

MD State Medical License 2000 - 2026
PA State Medical License 1997 - 2002
American Board of Radiology Radiation Oncology

Clinical Trials

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2003 Jun 01
Completed
Phase 3
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery Start of enrollment: 2008 Dec 01
Completed
Phase 2
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15
Completed
Phase 3
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis Start of enrollment: 2009 Nov 01
Completed
Phase 2, Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Start of enrollment: 2011 Feb 01
Completed
Phase 2
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
COMPLETED
PHASE2
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Completed
Phase 2
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer Start of enrollment: 2011 May 01
Terminated
Phase 3
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 2
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) Start of enrollment: 2019 Jul 26
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

1 citations
Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery.
Patricia A Ganz, Reena S Cecchini, Julia R White, Frank A Vicini, Douglas W Arthur
Journal of the National Cancer Institute. 2025-01-01
4 citations
Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy.
Daniel Song, Mateusz Dabkowski, Paulo Costa, Rizwan Nurani, Michael Kos
International Journal of Radiation Oncology, Biology, Physics. 2024-12-01
1 citations
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
Douglas M Dahl, Joseph P Rodgers, William U Shipley, M Dror Michaelson, Chin-Lee Wu
Journal of Clinical Oncology. 2024-12-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society for Radiation Oncology - ASTRO
Member
American College of Radiology - ACR
Fellow